UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

Example Bundle: Espranor-2mg-Lyophilisate-SE-BS-MPD-BBDL

Espranor 2 mg frystorkad tablett

MPID: SE-XXXXXXXXX-00051207
EURDID: 461

Full name: Espranor 2 mg frystorkad tablett

- Invented name part: Espranor

- Strength part: 2 mg

- Pharmaceutical dose form part: Frystorkad tablett

Name usage: Swedish (Kingdom of Sweden)

Authorised dose form: Oral lyophilisate

Legal status of supply: Medicinal product subject to special medical prescription

Domain: Human use

Resource status: Current

Product classification:

  • 100000097495 N07BC01

Marketing Authorisation 1 of 1

Authorisation number: 51207

Region: Kingdom of Sweden

Marketing authorisation holder: Etypharm

Identifier:

  • LOC-XXXXXXXX

Status: Valid (2015-07-16)

Package 1 of 2

PCID:

Description:
Blister, 28 tabletter (endos)

Marketing status:

  • Kingdom of Sweden: Marketed

Pack size:

  • 28 Tablet

Package: 1 Box (Cardboard)

Containing:

Package: 28 Blister (Aluminium) (PolyVinyl Chloride) (Orientated PolyAmide) (PolyEthylene TerePhthalate) (Paper)

Containing: 1 Tablet

Manufactured Item

Dose form: Oral lyophilisate

Unit of presentation: Tablet

Ingredient

Role: Active

Substance: Buprenorphine hydrochloride

Presentation strength: 2.156 milligram(s) / 1 tablet

Reference strength:
Buprenorphine 2 milligram(s) / 1 tablet

Package 2 of 2

PCID:

Description:
Blister, 7 tabletter (endos)

Marketing status:

  • Kingdom of Sweden: Marketed

Pack size:

  • 7 Tablet

Package: 1 Box (Cardboard)

Containing:

Package: 28 Blister (Aluminium) (PolyVinyl Chloride) (Orientated PolyAmide) (PolyEthylene TerePhthalate) (Paper)

Containing: 1 Tablet

Manufactured Item

Dose form: Oral lyophilisate

Unit of presentation: Tablet

Ingredient

Role: Active

Substance: Buprenorphine hydrochloride

Presentation strength: 2.156 milligram(s) / 1 tablet

Reference strength:
Buprenorphine 2 milligram(s) / 1 tablet

Administrable Product (1 of 1)

Dose form: Oral lyophilisate

Unit of presentation:

Route of administration:

  • Oral use

Ingredients:

Ingredient

Role: Active

Substance: Buprenorphine hydrochloride

Presentation strength: 2.156 milligram(s) / 1 tablet

Reference strength:
Buprenorphine 2 milligram(s) / 1 tablet